FMI
RARE icon

F/M Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

F/M Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,484
Closed -$1.69M – 422
2025
Q4 		$1.69M Buy
73,484
+11,731
+19% +$386K 0.06% 257
2025
Q3 		$1.86M Buy
61,753
+2,651
+4% +$79.5K 0.07% 252
2025
Q2 		$2.15M Buy
59,102
+788
+1% +$28.4K 0.08% 230
2025
Q1 		$2.11M Buy
58,314
+16,310
+39% +$679K 0.08% 222
2024
Q4 		$1.77M Buy
+42,004
New +$2.08M 0.07% 239

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

F/M Investments's RARE Position: Q1 2026 in Review

F/M Investments sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 73,484 shares — an estimated $1.69M sold.

F/M Investments first reported a position in RARE in Q4 2024 and held it in 5 quarters. The position peaked at $2.15M in Q2 2025. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • F/M Investments reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • F/M Investments sold 73,484 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.69M.
  • F/M Investments first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 5 quarters.
  • F/M Investments's Ultragenyx Pharmaceutical position peaked at $2.15M in Q2 2025.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on F/M Investments's 13F filing for Q1 2026, filed 11 May 2026.